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Cardiac surgery remains an important treatment option for
many patients with coronary artery disease, valvular heart dis-
ease and heart failure. Coronary artery remains the common-
est operation undertaken in most centres, but its proportion is
decreasing in the UK.1 More patients are undergoing mitral
and aortic valve procedures, both by conventional and novel
approaches including smaller incisions for conventional sur-
gery and the insertion of new devices using catheter-based de-
vices. This article will summarise publications from recent
years that are having an impact on the practice of cardiac
surgery.2. Coronary artery surgery
There are marked changes in patients coming for coronary ar-
tery surgery over time that have been shown clearly from the
analyses of large series from the USA and UK. A report from
the Society for Thoracic Surgeons (STS) database has de-
scribed the increasing risk proﬁle of patients coming to surgery
with fewer smokers, more patients with diabetes and more use
of the left internal mammary artery (LIMA) as a bypass con-
duit. Overall, there has been a signiﬁcant decline in postoper-
ative mortality and morbidity.2 Similar trends have been
reported in the UK from the national adult cardiac surgery
database, where there has been a greater than 50% reduction
in risk adjusted mortality since 2000, again with increasing risk
proﬁles, and more use of the internal mammary artery.1,3
However, despite some evidence for their efﬁcacy, off-pump
surgery and multiple grafts have not become widespread.1
3. Coronary artery surgery or PCI for angina
The major contemporary randomised clinical trial to inform
decision making in patients with multi-vessel coronary artery
disease is the Synergy between PCI with Taxus and Cardiac
Surgery (SYNTAX) trial. The study randomised 1800 patients
with previously treated three vessel or left main coronary ar-
tery disease or both in 85 sites in 17 countries across Europe
and the USA. The 1-year results were published in 2009, show-
ing that the percutaneous coronary intervention (PCI) group
had higher rates of the combined end point of major adverse
cardiac or cerebrovascular events and failed to achieve the pre-
deﬁned end point of non-inferiority.4 This difference was dri-
ven by a high rate of repeat revascularisation in the PCI
group (13.5% PCI, 5.9% coronary artery bypass grafting
(CABG)). The 1-year rates of death or myocardial infarction
(MI) were not different between the groups. These differences
persist over longer follow-up with 3-year MACCE rates (death
stroke, MI or repeat revascularisation) being higher in the PCIgroup (28%) than the CABG group (20%), again driven
mainly by repeat revascularisation, but there was no difference
in the primary safety end point or the incidence of stroke. On
subgroup analysis, there was no difference in major adverse
events in the patients with left main stem (LMS) stenosis,
but outcomes were worse following PCI in the three vessel sub-
group.5 Analysis of outcomes based on procedural risk from
the syntax score has shown at 4 years that the curves are
diverging overall, but with no difference in the low risk pa-
tients (http://www.syntaxscore.com).
In line with the data from SYNTAX, a large registry-based
study from the USA linked the ACCF National Cardiovascu-
lar registry and the STS adult cardiac surgery database to the
Medicare and Medicaid registries and used propensity scoring
to match patients who were 65 years or older undergoing PCI
and CABG. Four years after intervention there was a mortal-
ity advantage in the CABG group, which persisted in the
important subgroups.6
While the late outcomes of most higher risk patients with
multi-vessel coronary artery disease seem to be better with
CABG, in both randomised and registry-based studies, the
outcome following intervention for LMS stenosis is not so
clear cut, certainly during early follow-up. In a meta-analysis
of patients with unprotected LMS stenosis analysing 2905 pa-
tients from eight clinical studies, there was no signiﬁcant differ-
ence between the two groups with respect to mortality or a
composite end point of death, MI or stroke at 1 year.7 Another
meta-analysis of 3773 patients looking out to 3 years gave sim-
ilar ﬁndings.8 Analysis of the left main subgroup of the SYN-
TAX study also showed no difference up to 3 years.5,9 More
recently, the Premier of Randomised Comparison of Bypass
Surgery versus Angioplasty using Sirolimus-Eluting Stent in
Patients with Coronary Artery Disease trial has reported re-
sults of 300 patients in each arm to 2 years, and showed PCI
to be non-inferior, but the authors accept that the non-inferi-
ority margin was wide, leaving open the need for further stud-
ies.10 Similar ﬁndings have also been detected in a smaller
study.11 To understand better the safety and efﬁcacy of the
place of PCI for LMS stenosis, the Evaluation of Xience Prime
versus Coronary Artery Bypass Surgery for Effectiveness of
Left Main Revascularisation trial is ongoing in patients with
LMS disease and syntax scores of #32.12,13
4. ESC/EACTS revascularisation guidelines
The European Society for Cardiology and European Associa-
tion of Cardiothoracic Surgery published guidelines for revas-
cularisation in 2010 that were developed by a balanced writing
team of interventional cardiologists, non-interventional cardi-
ologists and surgeons. The guidelines recommend decision
making through an appropriately conﬁgured ‘heart team’
and suggest that surgery is the better option for revascularisa-
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disease.14 Data published since the guidelines were released,
including later analyses of the SYNTAX trial, have further
reinforced the evidence on which the guidelines are based. Po-
tential implications of these recommendations have been re-
ported,15,16 but detailed analyses of any changes in practice
are not yet available.5. Is off pump coronary artery surgery safe?
Controversy remains surrounding the relative beneﬁts of
undertaking coronary artery surgery with or without the car-
diopulmonary bypass machine.17,18 In the UK, around 20%
of cases are undertaken off pump but there are conﬂicting data
about safety and longer-term outcomes.1
Concern was raised from the ROOBY trial in which 2203
patients undergoing CABG were randomised to surgery on
or off pump. There was no signiﬁcant difference in 30-day
mortality, but there were a higher proportion of patients
receiving fewer grafts than planned in the off-pump group.
Of concern, there was a signiﬁcantly worse 1-year composite
end point of death, repeat revascularisation or non-fatal MI
and poorer graft patency in the off-pump group.19 Critics of
the study have commented that the trial enrolled low risk, male
patients who would be the least likely to beneﬁt from avoiding
cardiopulmonary bypass, the surgeons were inexperienced and
there was a high (12%) rate of intraoperative conversion to by-
pass surgery.20 Furthermore, endoscopic vein harvesting was
associated with worse outcomes at 1 year in the study (see fur-
ther below).21 In addition, Moller et al. have reported random-
ised trial data on 341 high risk (EuroSCORE> 5) patients
with three vessel disease undergoing surgery on- or off-pump
in the Best Bypass Surgery trial. There was no signiﬁcant dif-
ference in the primary outcome of adverse cardiac and cerebro-
vascular events during a median follow-up of 3.7 years,
although all cause mortality was higher in the off-pump
group.22
More reassuring data have recently been published from the
MASS 3 trial with 5-year follow-up from a single centre
with no difference in a composite end point of death, MI or
further revascularisation between the groups and from
the CORONARY study, which randomised 4752 patients to
on- or off- pump and showed no signiﬁcant difference in 30-
day mortality or the incidence of MI, stroke and renal fail-
ure.23,24 Later outcome data from this study are awaited with
interest.
There has also been a meta-analysis of 35 propensity score
studies on 123137 patients undergoing on- or off-pump sur-
gery. This suggested that off-pump surgery was superior for
short-term mortality and other outcomes.25 In a single centre
study of 14766 patients reported by Puskas et al. there was
no difference in operative mortality in the lowest risk quartile
but increasing beneﬁt for higher risk patients, which supports
the argument used by critics of the ﬁndings of the ROOBY
study.26 Similar ﬁndings have been reported on 349 survivors
of two randomised studies comparing on- and off-pump sur-
gery in which 199 patients had graft patency assessed, and in
299 patients health-related quality of life, with no difference
seen between the groups at 6–8 years.27
While the beneﬁts or otherwise of off-pump surgery are not
yet clearly deﬁned, there remains interest in optimising out-comes from on-pump surgery by reﬁning bypass techniques.
For example, a recent trial has drawn attention to how the
brain might be protected by using a minimal extracorporeal
circulation.28 In this randomised comparison of minimal ver-
sus conventional extracorporeal circulation, the minimal cir-
cuit was associated with improved cerebral perfusion during
cardiopulmonary bypass and improved neurocognitive perfor-
mance on direct testing at discharge, with evidence of sustained
effects at 3 and 14 months. The data suggest that some of the
advantages proposed by off-pump enthusiasts, particularly
cerebral protection, might be achieved by modifying on-pump
strategies.
6. Is endoscopic vein harvesting safe?
In line with other moves towards less invasive surgery, there
has been a signiﬁcant move towards harvesting the long saphe-
nous vein through minimally invasive, including endoscopic,
approaches but there remains some concern over safety. As de-
scribed previously, a subgroup analysis of the ROOBY trial
suggested that endoscopic vein harvesting was associated with
worse outcomes.21 A secondary analysis of patients from the
PREVENT IV trial at 3 years of follow-up also showed worse
outcomes for patients undergoing endoscopic harvesting, but
this ﬁnding has not been conﬁrmed in other observational
studies.29–31
7. Should bilateral internal mammary artery grafts be used for
coronary artery surgery?
It is generally accepted that using the LIMA graft to the left
anterior descending coronary artery is associated with better
inhospital mortality, long-term survival and freedom from an-
gina, and a number of observers suggest that if one mammary
is good, two would be better. Despite this, <10% of coronary
artery operations in the UK receive both internal mammary
arteries.1 To address this, the ART trial is a large randomised
study, which has now reported 1-year data on 1554 patients
receiving a single LIMA graft and 1548 receiving bilateral
mammary arteries (BIMA). It has been powered to look at sur-
vival at 10 years. The 1-year data show no mortality difference
between the groups but there was a three times increase in the
rate of sternal wound reconstruction in the BIMA group.32 In
view of our understanding of the timing of vein graft failure it
would have been surprising to see any beneﬁt from BIMA
grafting at this stage. Further supportive evidence for the ben-
eﬁcial effect of BIMA has been shown from a single centre pro-
pensity matched study of 928 BIMA versus 928 LIMA and
saphenous vein grafts reporting to 17 years with a survival
beneﬁt of 10% at 10 years and 18% at 15 years.33
There has been great interest in the use of the radial artery
as a conduit for coronary artery bypass surgery, with enthusi-
asts recommending its use, either alongside both internal mam-
mary arteries for a total arterial grafting approach or in
addition to a single mammary artery, to improve long-term
outcomes. However, a randomised study of 733 patients com-
paring radial artery grafts to saphenous veins has recently
shown similar graft patency at 1 year (both 89%).34 Of con-
cern, the radial artery was associated with a higher incidence
of vasospasm in this study and the saphenous vein had better
outcomes in diabetic patients. Further concern has been raised
46 B. Bridgewaterfrom a study using CT scanning to assess graft patency.35
However, there remains a number of reports claiming good
late patency rates.36–38
Most of the studies looking at comparative outcomes of dif-
ferent surgical strategies have relied on late outcomes, with
mortality being most important, and these data are obviously
difﬁcult to collect and they only provide useful information
many years ‘after the event’. To help provide useful and more
timely differential data, some workers have been looking at
techniques to assess preoperative risk other than clinical out-
comes such as per-operative injury to the left ventricular myo-
cardium. This is hard to quantify and was the subject of a
recent study from Oxford in which 40 patients underwent car-
diac MR before and after CABG with the serial assessment of
troponin I (TnI).39 TnI correlated closely with the mass of new
cardiac MR necrosis (r 0.83, p< 0.001), with sensitivity and
speciﬁcity values of 75% and 87%, making it a robust means
of diagnosing this type of MI.
Alongside analyses of ways to optimise operative surgical
strategy, there is also an increasing focus on non-mortality
postoperative outcomes and pathways. For example, a study
has examined the implications of postoperative anaemia in a
retrospective analysis of 2553 CABG patients included in the
IMAGINE trial.40 They showed that postoperative anaemia
sustained for >50 days is associated with an increased inci-
dence of cardiovascular events during the ﬁrst 3 months. The
researchers also found that ACE inhibition slowed recovery
from postoperative anaemia and increased the incidence of
cardiovascular events after CABG, although the mechanism
and therapeutic implication of this observation is not clear.
It has also become increasingly accepted that formal cardiac
rehabilitation is beneﬁcial to enhance recovery after CABG
surgery, with an emphasis being placed on exercise pro-
grammes. While the best means of delivering these pro-
grammes are unclear, a Canadian study favoured a home-
based strategy based on a 6-year follow-up of patients ran-
domised to hospital versus telephone-monitored home-based
exercise training.418. Coronary artery surgery for heart failure?
The STICH trial has showed that there is no difference in
survival between patients with heart failure and poor left ven-
tricular function, randomised to either medical therapy or
medical therapy plus CABG. In a subset of this study in
which myocardial viability was assessed, the presence of via-
ble myocardium was associated with better survival overall,
but this was not signiﬁcant after adjusting for other baseline
variables.42,43 Taken at face value these are profound ﬁndings
for the practice of coronary artery surgery and are at odds
with many physicians’ and surgeons’ preconceptions, but
some observers have questioned whether the ﬁndings of the
trial are valid because of difﬁculties in trial recruitment lead-
ing to changes in trial design after instigation alongside a
crossover rate of 17% to CABG, therefore underestimating
the beneﬁts of surgery and suggesting that CABG should still
be considered if CAD is severe and viable myocardium is
seen.44 For example, a recent propensity matched study of
CABG versus medical therapy in these patients (designed to
mimic the STICH trial inclusion) showed a clear survival
advantage of CABG at 10 years.459. Aortic valve surgery
The practice of aortic valve surgery is changing. In the USA,
an analysis of 108 687 isolated aortic valve replacement
(AVR) patients from 1997 to 2006 was reported in 2009.46
Morbidity and mortality have fallen despite gradual increases
in patient age and overall risk proﬁle, alongside an increase in
biological valve use. Similar trends have been seen in the UK
with a report of 41227 patients between 2004 and 2009 with
an overall inhospital mortality of 4.1%. The annual number
increased by 20%, with signiﬁcant increases in the mean age
of patients with aortic stenosis, octogenarians, the proportion
of high-risk patients and again those receiving biological valves
(which is almost certainly inﬂuenced by surgeons’ views of bet-
ter longevity of modern biological valves and the promise of a
transcatheter valve solution for subsequent valve failure).47
Over this time, inhospital mortality decreased from 4.4% to
3.7%.48 While transcatheter valve insertion (TAVI) (see below)
is having an impact on valve surgery, in contrast to just erod-
ing the numbers of conventional valve operations, it has been
reported that starting a TAVI service may increase overall aor-
tic valve interventions, including those for conventional
surgery.49
There remains some controversy about the timing of sur-
gery in asymptomatic aortic stenosis (see parallels with mitral
valve repair below). Some work is being produced suggesting
beneﬁts from earlier intervention but other observers have
published data suggesting beneﬁts and safety of the watchful
waiting approach.50–53
10. Transcatheter valve insertion
The major change in the treatment of patients with aortic ste-
nosis in recent years has been the advent of TAVI, which has
now been shown to be a good option for the treatment of some
patients with aortic stenosis. The Partner study Cohort A trial
of 358 patients who were not considered suitable for conven-
tional AVR showed that TAVI decreased the rate of mortality
at 1 year (from 51% to 31%) and reduced cardiac symptoms
compared with conventional treatment.54 The 2-year results
have also been reported showing persistent survival advantage,
but a high rate of stroke in the TAVI group, due to more
ischaemic strokes in the ﬁrst 30 days after the procedure and
more haemorrhagic events thereafter. The rate of rehospitali-
sation was 35% in the TAVI group and 72% in the conven-
tional group. Quality of life studies on these patients using
the Kansas City Cardiomyopathy Questionnaire and the SF-
12 showed signiﬁcant beneﬁts in the TAVI group going out
to 1 year.55 An economic analysis of these data demonstrated
an incremental cost per life-year gained that was well within
the acceptable range.56
TAVI has also been shown to be comparable with conven-
tional aortic valve surgery. In the Partner study Cohort B, 699
patients with severe aortic stenosis who were deemed to be of
high risk were randomised to TAVI or conventional surgery.57
There was no signiﬁcant difference in mortality rates at
30 days (3.4% TAVI and 6.5% conventional surgery) or 1 year
(24.2% TAVI, 26.8% conventional surgery). Two-year data
have also been reported, again showing no difference in mor-
tality rates.58 Procedural complication rates were different be-
tween the groups, with major vascular complications being
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set atrial ﬁbrillation (AF) more common in conventional sur-
gery. A number of large registry studies have also conﬁrmed
acceptable procedural and longer-term outcomes.59–63
Transcatheter aortic valves are now being inserted in
increasing numbers through the femoral artery, trans-apically
directly via the left ventricle and through the aortic ap-
proach.64–66 In response to potential beneﬁts from less invasive
approaches, there has also been increasing interest in conduct-
ing ‘conventional’ surgery through a variety of smaller inci-
sions including mini-sternotomy, para-sternotomy, transverse
sternotomy, and right anterior thoracotomy. Various studies
including single centre experiences and meta-analyses have
shown that it can be applied safely in expert centres.67,68
Alongside less invasive approaches, to minimise insertion times
and allow easier valve implantation through small incisions,
various novel aortic valves are being developed and tested
which have ‘sutureless’ implantation techniques.69,70
A ﬁnal word on aortic valve surgery and TAVI is that there
are now consensus statements produced about the practice of
TAVI and to understand better how to achieve optimal out-
comes from conventional AVR, health service research studies
have shown that the outcomes of surgery are better for higher
risk patients under high volume surgeons, which lay down a
challenge for the conﬁguration of surgical services for these
patients.71,7211. Mitral valve surgery
The major advances in understanding of mitral valve surgery
in recent years are related to mitral valve repair. It is now well
accepted that repair is a better option than replacement for
most patients with degenerative mitral valve disease, and that
inhospital and later mortality outcomes are dependent on the
degree of symptoms and left ventricular dysfunction at the
time of surgery. Evidence from the UK suggests that many pa-
tients are still being referred late in the disease process with
47% of patients having NYHA class 3 or 4 symptoms and
31% of people displaying left ventricular (LV) ejection frac-
tions of <50% at the time of surgery.1
Surgical treatment for mitral valve disease is changing over
time, and a report on 58370 patients with isolated mitral regur-
gitation from the STS database in the 8 years to December
2007 showed a progressive adoption of mitral repair rather
than replacement from 51% to 69%. There was also a decrease
in the use of mechanical rather than biological valves over that
time from 68% to 37% (and there are similar data from the
UK).1,73 This, of course, indicates that one in three patients
with severe MR undergo a valve replacement, and this remains
a concern from the perspective of health service delivery.74
The major controversy around patients with severe MR is
around the timing of surgery. There are no randomised trial
data to support early surgery or ‘watchful waiting’ and so
the evidence is derived from observation studies. In 2005, Enri-
quez-Sarano and colleagues from the Mayo Clinic reported an
observational study on 456 patients with symptomatic organic
mitral regurgitation, showing that patients with an effective
regurgitant oriﬁce area of >40 mm2 had a survival at 5 years
that was lower than expected.75 On this basis, they recom-
mended mitral valve repair for patients with genuinely severe
mitral regurgitation, purely on the basis of symptoms, irrespec-tive of left ventricular size or function. Similar ﬁndings have
been reported from Korea on 447 consecutive asymptomatic
patients undergoing early surgery or conventional treatment
strategy with early surgery associated with improved long-term
event rates by decreasing cardiac mortality and congestive
heart failure hospitalisation.76 A further observational study
of 192 patients followed up for 8.5 years, divided into an early
surgery and a conservative group, also showed better out-
comes in the conservative group.77
Conversely, Rosenhek et al. have reported outcomes on 132
patients and only intervened at the time of onset of symptoms,
left ventricular impairment or signiﬁcant LV dilatation accord-
ing to the accepted guidelines of the time of onset of symp-
toms, left ventricular impairment or signiﬁcant LV
dilatation.78,79 Overall, late outcomes were excellent, and only
a third of the patients required surgery during then follow-up
period of 5 years, but it is obviously important that if this
strategy is followed, then follow-up must be robust and
comprehensive.
Guidance from the American College of Cardiology/Amer-
ican Heart Association from 2006 suggests that early surgery
should be considered for asymptomatic patients at low proce-
dural risk in ‘experienced centres’ as long as the likelihood of
successful repair is >90%.80 An attempt has been made from
a UK consensus study to describe the criteria associated with
an experienced centre.81 However, if one comes from a surgical
epidemiologal approach there must be some concern about an
overall early surgery strategy for these patients.74 In a report of
13614 patients with mitral regurgitation undergoing surgery
from the STS database there was a marked variation in the
overall volumes per year, and higher volume centres showed
higher rates of valve repair and lower risk adjusted mortality.82
Again from the STS database in an analysis of 28507 patients
undergoing isolated mitral valve surgery with or without tri-
cuspid valve or concomitant AF surgery under 1088 surgeons,
the mean rate of repair by surgeons was only 41%. The median
annual number of operation was ﬁve (1–166) and increasing
surgeon volume was independently associated with increased
probability of repair.83 The consensus-based opinion study
from the UK has suggested that hospitals should be undertak-
ing more than 50 mitral repair operations each year to get opti-
mal outcomes, and individual surgeons should be doing more
than 25. It seems that many hospitals and surgeons fall short
of this. Offering an early surgical strategy in the absence of
assurance about high repair rates and excellent durability of
repair procedures may not be in the patients’ best interests.
There have been some developments in the techniques of
mitral valve repair with a move towards more use of artiﬁcial
chordae tendinae and preservation of leaﬂet tissue rather than
resection and the increasing use of less invasive techniques.84–
89 While there are a growing number of reports suggesting the
safety of minimally invasive approaches, there is signiﬁcant
anecdotal reporting of the concern about these techniques
and their safety.
There are also developments in catheter-based treatments
of mitral regurgitation, and the Endovascular valve edge to
edge repair (EVEREST 2) trial has reported the outcomes of
78 patients at high risk from conventional surgery having an
‘edge to edge’ treatment with the ‘MitralClip’ showing a proce-
dural mortality of 7.7% with a reduction in MR in most pa-
tients with an improvement in clinical symptoms in three-
fourths of the patients.90
48 B. Bridgewater12. Risk modelling
The assessment of operative risk in cardiac surgery is impor-
tant to guide decision making (e.g., conventional surgery or
TAVI for patients with aortic stenosis), support informed con-
sent and for governance and public reporting of hospital and
surgeon mortality rates. The STS scores were published in
2009 after analysing data from the STS database, with models
published for coronary artery surgery, valve surgery and com-
bined coronary and valve surgery. These model a standard set
of outcomes for all procedures including mortality, stroke,
reoperation, renal failure, deep sternal wound infection, pro-
longed ventilation, composite major morbidity, prolonged
length of stay and short length of stay.91–94
More recently, it has been accepted that the EuroSCORE is
no longer suitable for contemporary practice and the Euro-
SCORE 2 has been published.95,96 Unlike the STS models,
which are procedure speciﬁc, the EuroSCORE 2 is a generic
model covering all cardiac surgery, which have some potential
strengths and weaknesses. It was derived from a patient popu-
lation of 22381 consecutive patients undergoing major cardiac
surgery in 154 hospitals in 43 countries over a 12-week period
(May 2010 to July 2010). The ﬁelds required to derive the score
have been updated from the previous model and include creat-
inine clearance, modiﬁcations to the categorisation of LV ejec-
tion fraction and introduction of a limited mobility ﬁeld.96,97
The ‘weight of intervention’ is also dealt with differently from
the original EuroSCORE model. The developers report good
discrimination and calibration and it is likely that this model
will be widely adopted, but will require robust external valida-
tion. There remains debate about the derivation and use of this
type of model.98
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